Adcytherix is a clinical‑stage biopharma that creates next‑generation antibody‑drug conjugates (ADCs) by linking clinically validated antibodies to innovative payloads derived from already approved cancer drugs. Their platform uses advanced conjugation chemistry to improve stability, control payload release, and overcome resistance mechanisms, expanding the therapeutic window for high‑unmet‑need solid tumors. The company’s pipeline targets cancers that are refractory to existing ADCs, offering more precise and tolerable oncology therapies.

Altamira Therapeutics provides the xPhore™ platform, a peptide‑based nanoparticle system that enables efficient delivery of siRNA, mRNA, circRNA, and DNA therapeutics to extra‑hepatic tissues for pharma and biotech partners. It also markets Bentrio®, a preservative‑free nasal spray for allergic rhinitis, and develops CNS treatments for inner‑ear and neurological disorders.

AM Pharma is developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, as an enzyme replacement therapy for adult hypophosphatasia (HPP). The subcutaneous treatment restores alkaline phosphatase activity, lowering disease‑related pyridoxal‑5′‑phosphate and inorganic pyrophosphate levels, which improves bone mineralization, muscle function, and pain. Phase 1b data show dose‑dependent normalization of HPP biomarkers and a favorable safety profile, positioning ilofotase alfa for Phase 2 trials to address the unmet need in adult HPP patients.

Arkhn provides a healthcare data warehouse platform that enhances data interoperability by utilizing sovereign health data repositories. This solution enables healthcare institutions to efficiently access, manage, and leverage their fragmented data for improved patient care and research outcomes.

Arkhn Assistant is a generative‑AI platform that ingests PDF, Word and scanned documents, extracts clinical data, and automatically generates structured medical reports using predefined or custom templates. It is delivered as a web application and Microsoft Word add‑in, with optional secure integration to hospital information systems for bidirectional data flow, and operates in an HDS‑certified, ISO 27001‑compliant environment.

Asceneuron develops oral therapeutics that target tau pathology to treat neurodegenerative disorders, including Alzheimer’s disease and orphan tauopathies. The company addresses the high unmet medical needs in these conditions by blocking the progression of tau-related neurodegeneration.

Avidicure develops Actibody, a proprietary triple‑agonistic antibody platform that simultaneously delivers primary activation, co‑stimulatory, and cytokine signals to immune cells, enabling sustained and localized immune activation. By genetically fusing engineered domains onto a human IgG scaffold and using AI‑driven in‑silico design, the molecules provide conditional activation at the target site, enhancing potency while reducing systemic toxicity for oncology and autoimmune applications.

Axithra develops a platform utilizing proprietary optical and photonics technology to rapidly and accurately measure drug concentrations in blood, enabling personalized treatment plans for patients. The initial focus is on optimizing beta-lactam antibiotic therapies in intensive care units, enhancing drug effectiveness and minimizing adverse reactions.

Bioserenity provides an integrated neuroscience platform that combines portable, FDA‑cleared EEG and sleep‑monitoring devices with cloud‑based AI analytics and telemedicine tools. The solution streams high‑quality neurophysiological data to a secure cloud, where AI automatically preprocesses signals, detects clinical events, and generates structured reports that clinicians can review and share remotely, enabling faster diagnosis of neurological and sleep disorders.

BliNK Biomedical provides a B‑cell technology platform that directly screens and isolates individual antibody‑producing cells from human and other animal sources, using its proprietary ISAAC and VIVA|Screen systems. The high‑throughput, deep‑mining approach can detect extremely rare antibody‑secreting cells across multiple species, enabling the generation of unique therapeutic antibody candidates that are difficult to obtain with conventional methods.

Brink Therapeutics develops next-generation recombinase enzymes designed for ultra-precise and efficient gene editing. These enzymes aim to enable large-scale production of cell and gene therapies for treating cancer and genetic disorders.

Cardiologs provides a cloud-based, vendor-neutral arrhythmia diagnostic software powered by medical-grade AI, capable of detecting over 20 types of arrhythmia events. The platform enhances remote cardiac monitoring by integrating smartwatch ECGs into clinical workflows, making expert cardiac care more accessible and scalable for healthcare professionals worldwide.

Charles offers personalized teleconsultations with medical specialists to address men's health issues, including sexual health, sleep disorders, and hair loss. The platform provides tailored diagnostics and ongoing support, ensuring men can manage their health concerns effectively from home.

Coave Therapeutics develops targeted gene therapies using its proprietary ALIGATER™ platform, which creates ligand‑conjugated AAV vectors that bind selectively to ocular tissues such as the suprachoroidal space. This technology enables highly specific, safer delivery of therapeutic genes for retinal vascular diseases like neovascular age‑related macular degeneration and diabetic macular edema, aiming to provide durable, injection‑free treatments. The modular platform can be applied to other vectors and disease areas, offering pharmaceutical and biotech partners a plug‑and‑play solution for precise gene therapy delivery.

Corteria Pharmaceuticals develops first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonists to treat worsening and acute decompensated heart failure, targeting specific patient subpopulations with high unmet medical needs. The company employs innovative patient stratification methods to identify individuals most likely to benefit from its therapies, addressing the critical issue of fluid retention and pulmonary congestion in heart failure patients.

DAMAE Medical develops the deepLive™ imaging system, which utilizes line-field confocal optical coherence tomography (LC-OCT) technology to provide high-resolution, 3D imaging of skin lesions. This non-invasive method significantly reduces the rate of unnecessary biopsies and improves early detection of skin cancers, addressing the challenge of missed diagnoses in clinical practice.

Deep offers a suite of validated sleep solutions, including at-home diagnostics, cognitive therapy, and telemedicine consultations with licensed specialists, all accessible through a mobile app. The platform addresses the widespread issue of poor sleep quality by providing personalized coaching and tailored treatment plans to improve sleep health and overall well-being.

The SYNTAX® Platform provides enzymatic, on‑demand synthesis of high‑quality single‑stranded DNA oligonucleotides. Laboratories can generate custom ssDNA overnight, enabling faster synthetic biology workflows for biotech, pharma, CROs and core facilities.

Elkedonia is developing a novel neuroplastogen for depression treatment, utilizing a precision medicine approach to induce neuroplasticity. This therapeutic candidate targets intracellular neuronal events with a unique mechanism of action, aiming to provide fast-acting relief without common antidepressant side effects.

Emergence is a biopharmaceutical company developing antibody-drug conjugates (ADCs) that target specific cancer cells, aiming to improve treatment outcomes for cancers with significant unmet medical needs. Their approach enhances the precision of cancer therapies, reducing systemic toxicity while increasing efficacy for patients facing aggressive malignancies.

EvlaBio is a biotech company developing targeted therapeutics to treat diseases with significant unmet medical needs, utilizing advanced drug discovery techniques and biomarker identification. Their focus is on creating effective treatment options for conditions that currently lack adequate therapies, improving patient outcomes and quality of life.

Flamingo Therapeutics develops RNA-targeted therapies that specifically modulate undruggable transcription factors and splice variants associated with various cancer types. Their discovery engine utilizes advanced antisense chemistry to identify and target RNA elements, addressing significant gaps in treatment options for patients with difficult-to-treat cancers.

Ganymed Robotics develops robotic systems specifically designed for orthopedic joint replacement surgeries, enhancing precision and consistency during procedures. Their technology aims to improve patient outcomes and streamline the surgical workflow, addressing inefficiencies in traditional surgical methods.

Germitec offers automated UV‑C high‑level disinfection systems that sterilize ultrasound, TEE and ENT endoscopic probes without chemicals. The one‑button platform delivers validated UV‑C doses in seconds to minutes, logs each cycle for traceability, and integrates with hospital quality‑control systems, reducing waste, staff exposure and turnaround time while maintaining regulatory compliance.